Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

Detalles Bibliográficos
Autores principales: A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287808/
http://dx.doi.org/10.1186/1745-6215-12-S1-A88
_version_ 1782224748280807424
author A’Hern, Roger
DeBono, Johann
Sandhu, Shahneen
Kalaitzaki, Eletheria
Usdin, Martine
Hall, Emma E
author_facet A’Hern, Roger
DeBono, Johann
Sandhu, Shahneen
Kalaitzaki, Eletheria
Usdin, Martine
Hall, Emma E
author_sort A’Hern, Roger
collection PubMed
description
format Online
Article
Text
id pubmed-3287808
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32878082012-02-28 Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups A’Hern, Roger DeBono, Johann Sandhu, Shahneen Kalaitzaki, Eletheria Usdin, Martine Hall, Emma E Trials Oral Presentation BioMed Central 2011-12-13 /pmc/articles/PMC3287808/ http://dx.doi.org/10.1186/1745-6215-12-S1-A88 Text en Copyright ©2011 A’Hern et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation
A’Hern, Roger
DeBono, Johann
Sandhu, Shahneen
Kalaitzaki, Eletheria
Usdin, Martine
Hall, Emma E
Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_full Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_fullStr Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_full_unstemmed Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_short Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_sort phase ii investigation of a parp inhibitor (olaparib) in castration resistant prostate cancer (crpc) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287808/
http://dx.doi.org/10.1186/1745-6215-12-S1-A88
work_keys_str_mv AT ahernroger phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT debonojohann phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT sandhushahneen phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT kalaitzakieletheria phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT usdinmartine phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT hallemmae phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups

Ejemplares similares